Dry mixing transformed micro-particles of a drug from a highly crystalline to a highly amorphous state

Pharmaceutical Development and Technology

Volumn 14, Issue 3, 2009, Pages 233-239

  Höckerfelt, Mina Heidarian ^a   Nyström, Christer ^a   Alderborn, Göran ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Activation; Crystallinity; Mixing; Solubility

Indexed keywords

CRYSTALLIN; GLASS; GRISEOFULVIN;

ARTICLE; MIXER; PARTICLE SIZE; PRIORITY JOURNAL; SAMPLE; SOLID STATE; TIME; CHEMISTRY; CRYSTALLIZATION; MECHANICAL STRESS;

CRYSTALLIZATION; GRISEOFULVIN; PARTICLE SIZE; STRESS, MECHANICAL;

EID: 70350654533     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802585252     Document Type: Article

References (34)

1. Hüttenrauch R, Fricke S, Zielke P. Mechanical activation of pharmaceutical systems. Pharm Res. 1985;6:302-306.
2. Shalaev E, Shalaeva M, Zografi G. The effect of disorder on the chemical reactivity of an organic solid, tetraglycine methyl ester: change of the reaction mechanism. J Pharm Sci. 2002;91:584-593.
3. Yonemochi E, Ueno Y, Ohmae T, Oguchi T, Nakajima SI, Yamamoto K. Evaluation of amorphous ursodeoxycholic acid by thermal methods. Pharm Res. 1997;14:798-803.
4. Yonemochi E, Kitahara S, Maeda S, Yamamura S, Oguchi T, Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur J Pharm Sci. 1999;7:331-338.
5. Mura P, Cirri M, Faucci MT, Gines-Dorado JM, Bettinetti GP. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal. 2002;30:227-237.
6. Chung HY, Yonemochi E, Saitoh T, Terada K, Tozuka Y, Oguchi T, Yamamoto K, Chung HY, Choi WS. Factors affecting the apparent solubility of ursodeoxycholic acid in the grinding process. Int J Pharm. 2003;255:49-56.
7. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int. J. Pharm. 2002;241:73-85.
8. Mackin L, Sartnurak S, Thomas I, Moore S. The impact of low levels of amorphous material
9. Hüttenrauch R. Molekulargalenik als grundlage moderner arzneiformung. Acta Pharm Technol. 1978;(Suppl. 6):55-127.
10. Mosharraf M, Nyström C. The effect of dry mixing on the apparent solubility of hydrophobic, sparingly soluble drugs. Eur J Pharm Sci. 1999;9:145-156.
11. Kendall K. The impossibility of comminuting small particles by compression. Nature (London) 1978;272:710-711.
12. Roberts RJ, Rowe RC. Brittle/ductile behaviour in pharmaceutical materials used in tabletting. Int J Pharm. 1987;36:205-209.
13. Alderborn G, Nyström C. Studies on direct compression of tablets XIV. The effect of powder fineness on the relation between tablet permeametry surface area and compaction pressure. Powder Technol. 1985;44:37-42.
14. European Pharmacopoeia. 5th ed. Council of Europe, Strasbourg; 2005.
15. Bisrat M, Anderberg EK, Barnett MI, Nyström C. Physicochemical aspects of drug release. XV. Investigation of diffusional transport in dissolution of suspended, sparingly soluble drugs. Int J Pharm. 1992;80:191-201.
16. Ahmed H, Buckton G, Rawlins DA. Crystallisation of partially amorphous griseofulvin in water vapour: Determination of kinetic parameters using isothermal heat conduction microcalorimetry. Int J Pharm. 1998;167:139-145.
17. Angberg M, Nyström C, Castensson S. Evaluation of heat- conduction microcalorimetry in pharmaceutical stability studies. V. A new approach for continuous measurements in abundant water vapour. Int J Pharm. 1992;81:153-167.
18. Angberg M, Nyström C, Castensson S. Evaluation of heat- conduction microcalorimetry in pharmaceutical stability studies. VI. Continuous monitoring of the interaction of water vapour with powders and powder mixtures at various relative humidities. Int J Pharm. 1992;83:11-23.
19. Hermans PH, Weidinger A. Quantitative X-ray investigations on the crystallinity of cellulose fibers. A background analysis. J Appl Phys. 1948;19:491-506.
20. Suryanarayanan R, Mitchell AG. Evaluation of two concepts of crystallinity using calcium gluceptate as a model compound. Int J Pharm. 1985;24:1-17.
21. Duncan-Hewitt WC, Grant DJW. True density and thermal expansivity of pharmaceutical solids: Comparison of methods and assessment of crystallinity. Int J Pharm. 1986;28:75-84.
22. Pikal MJ, Lukes AL, Lang JE, Gaines K. Quantitative crystallinity determinations for β-lactam antibiotics by solution calorimetry: correlations with stability. J Pharm Sci. 1978;67:767-773.
23. Hendriksen BA. Characterization of calcium fenoprofen 1. Powder dissolution rate and degree of crystallinity. Int J Pharm. 1990;60:243-252.
24. Black DB, Lovering EG. Estimation of the degree of crystallinity in digoxin by X-ray and infrared methods. J Pharm Pharmacol. 1977;29:684-687.
25. Gustafsson C, Lennholm H, Iversen T, Nyström C. Comparison of solid-state NMR and isothermal microcalorimetry in the assessment of the amorphous component of lactose. Int J Pharm. 1998;174:243-252.
26. Sebhatu T, Angberg M, Ahlneck C. Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int J Pharm. 1994;104:135-144.
27. Saleki-Gerhardt A, Ahlneck C, Zografi G. Assessment of disorder in crystalline solids. Int J Pharm. 1994;101:237-247.
28. Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci. 2002;91:492-507.
29. Yonemochi E, Inoue Y, Buckton G, Moffat A, Oguchi T, Yamamoto K. Differences in crystallisation behaviour between quenched and ground amorphous ursodeoxycholic acid. Pharm Res. 1999;16:835-840.
30. Ha A, Cohen I, Zhao X, Lee M, Kivelson D. Supercooled liquids and polyamorphism. J Phys Chem. 1996;100:1-4.
31. Mosharraf M, Nyström C. Apparent solubility of drugs in partially crystalline systems. Drug Dev Ind Pharm. 2003;29:603-622.
32. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397-404.
33. Bahl D, Bogner RH. Amorphization of indomethacin by cogrinding with neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res. 2006;23:2317-2325.
34. Hilden LR, Morris KR. Physics of amorphous solids. J Pharm Sci. 2004;93:3-12.